77.85
-2.44(-3.04%)
Currency In USD
| Previous Close | 80.29 |
| Open | 79.4 |
| Day High | 79.4 |
| Day Low | 75.61 |
| 52-Week High | 83 |
| 52-Week Low | 11.17 |
| Volume | 161,801 |
| Average Volume | 170,431 |
| Market Cap | 860.99M |
| PE | -30.77 |
| EPS | -2.53 |
| Moving Average 50 Days | 66.65 |
| Moving Average 200 Days | 36.98 |
| Change | -2.44 |
If you invested $1000 in Palvella Therapeutics, Inc. (PVLA) since IPO date, it would be worth $4,579.41 as of November 12, 2025 at a share price of $77.85. Whereas If you bought $1000 worth of Palvella Therapeutics, Inc. (PVLA) shares 0 years ago, it would be worth $4,579.41 as of November 12, 2025 at a share price of $77.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
GlobeNewswire Inc.
Nov 06, 2025 12:30 PM GMT
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering f
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
GlobeNewswire Inc.
Nov 05, 2025 11:00 AM GMT
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients QTORIN™ pitavastatin has th
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
GlobeNewswire Inc.
Nov 04, 2025 12:30 PM GMT
WAYNE, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare